Patents by Inventor David Schaer
David Schaer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11897962Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.Type: GrantFiled: August 21, 2020Date of Patent: February 13, 2024Assignees: AGENUS INC., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Volker Seibert, Olivier Léger, Marc Van Dijk, Taha Merghoub, David Schaer, Gerd Ritter, Takemasa Tsuji
-
Publication number: 20230406946Abstract: The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.Type: ApplicationFiled: August 22, 2022Publication date: December 21, 2023Inventors: Nicholas S. WILSON, Jeremy D. WAIGHT, Gerd RITTER, David SCHAER, Daniel HIRSCHHORN-CYMERMAN, Taha MERGHOUB, Ekaterina V. BREOUS-NYSTROM, Volker SEIBERT, Takemasa TSUJI, Olivier LÉGER, Dennis J. UNDERWOOD, Marc VAN DIJK
-
Publication number: 20230399413Abstract: The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.Type: ApplicationFiled: August 22, 2022Publication date: December 14, 2023Inventors: Nicholas S. WILSON, Jeremy D. WAIGHT, Gerd RITTER, David SCHAER, Daniel HIRSCHHORN-CYMERMAN, Taha MERGHOUB, Ekaterina V. BREOUS-NYSTROM, Volker SEIBERT, Takemasa TSUJI, Olivier LÉGER, Dennis J. UNDERWOOD, Marc VAN DIJK
-
Publication number: 20230330225Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: ApplicationFiled: March 21, 2023Publication date: October 19, 2023Inventors: Marc VAN DIJK, Cornelia Anne MUNDT, Gerd RITTER, David SCHAER, Jedd David WOLCHOK, Taha MERGHOUB, Nicholas S. WILSON, David Adam SAVITSKY, Mark Arthur FINDEIS, Dennis J. UNDERWOOD, Jean-Marie CUILLEROT, Igor Proscurshim, Olga SHEBANOVO
-
Publication number: 20230167186Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.Type: ApplicationFiled: September 8, 2022Publication date: June 1, 2023Inventors: Marc VAN DIJK, Ekaterina V. BREOUS-NYSTROM, Volker SEIBERT, Gerd RITTER, David SCHAER, Daniel HIRSCHHORN-CYMERMAN, Taha MERGHOUB, Hao TANG, David A. SAVITSKY, Jeremy WAIGHT, Nicholas S. WILSON
-
Patent number: 11638755Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: December 14, 2020Date of Patent: May 2, 2023Assignees: Agenus Inc., Ludwig Institute for Cancer Research Ltd., Memorial Sloan-Kettering Cancer CenterInventors: Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, Nicholas Stuart Wilson, David Adam Savitsky, Mark Arthur Findeis, Dennis John Underwood, Jean-Marie Cuillerot, Igor Proscurshim, Olga Shebanova
-
Publication number: 20230108348Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.Type: ApplicationFiled: September 8, 2022Publication date: April 6, 2023Inventors: Marc VAN DIJK, Ekaterina V. BREOUS-NYSTROM, Volker SEIBERT, Gerd RITTER, David SCHAER, Daniel HIRSCHHORN-CYMERMAN, Taha MERGHOUB, Hao TANG, David A. SAVITSKY, Jeremy WAIGHT, Nicholas S. WILSON
-
Publication number: 20230039577Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.Type: ApplicationFiled: June 22, 2022Publication date: February 9, 2023Inventors: Ana M. GONZALEZ, Nicholas S. Wilson, Dennis J. Underwood, Volker Seibert, Olivier Léger, Marc Van Dijk, Roberta Zappasodi, Taha Merghoub, Jedd David Wolchok, David Schaer, Gerd Ritter, Takemasa Tsuji
-
Publication number: 20220389107Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and/or human GITR receptor (GITR), including multispecific antibodies that bind, e.g., to OX40 and GITR, and compositions comprising such antibodies. The antibodies disclosed herein modulate OX40 and/or GITR activity e.g., enhance, activate, induce, reduce, deactivate, or inhibit OX40 and/or GITR activity. The present disclosure also provides methods for treating disorders, such as cancer, autoimmune diseases or disorders, or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and/or human GITR and modulates OX40 and/or GITR activity.Type: ApplicationFiled: May 9, 2022Publication date: December 8, 2022Inventors: Nicholas S. WILSON, Jeremy D. WAIGHT, Dennis J. UNDERWOOD, Ekaterina V. BREOUS-NYSTROM, Gerd RITTER, David SCHAER, Daniel HIRSCHHORN-CYMERMAN, Taha MERGHOUB, Marc VAN DIJK
-
Publication number: 20220380479Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and/or human GITR receptor (GITR), including multispecific antibodies that bind, e.g., to OX40 and GITR, and compositions comprising such antibodies. The antibodies disclosed herein modulate OX40 and/or GITR activity e.g., enhance, activate, induce, reduce, deactivate, or inhibit OX40 and/or GITR activity. The present disclosure also provides methods for treating disorders, such as cancer, autoimmune diseases or disorders, or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and/or human GITR and modulates OX40 and/or GITR activity.Type: ApplicationFiled: May 9, 2022Publication date: December 1, 2022Inventors: Nicholas S. WILSON, Jeremy D. WAIGHT, Dennis J. UNDERWOOD, Ekaterina V. BREOUS-NYSTROM, Gerd RITTER, David SCHAER, Daniel HIRSCHHORN-CYMERMAN, Taha MERGHOUB, Marc VAN DIJK
-
Publication number: 20220372149Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: ApplicationFiled: May 9, 2022Publication date: November 24, 2022Inventors: Marc VAN DIJK, Cornelia Anne MUNDT, Gerd RITTER, Jedd David WOLCHOK, Taha MERGHOUB, Roberta ZAPPASODI, Rikke Baek HOLMGAARD, David SCHAER, David Adam SAVITSKY, Nicholas Stuart WILSON
-
Patent number: 11472883Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.Type: GrantFiled: March 3, 2020Date of Patent: October 18, 2022Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Marc Van Dijk, Ekaterina V. Breous-Nystrom, Volker Seibert, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Hao Tang, David A. Savitsky, Jeremy Waight, Nicholas S. Wilson
-
Patent number: 11447557Abstract: The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.Type: GrantFiled: December 2, 2016Date of Patent: September 20, 2022Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Nicholas S. Wilson, Jeremy D. Waight, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Ekaterina V. Breous-Nystrom, Volker Seibert, Takemasa Tsuji, Olivier Léger, Dennis J. Underwood, Marc Van Dijk
-
Publication number: 20220267443Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: ApplicationFiled: January 24, 2022Publication date: August 25, 2022Inventors: Marc Van DIJK, Cornelia Anne MUNDT, Gerd RITTER, David SCHAER, Jedd David WOLCHOK, Taha MERGHOUB, David Adam SAVITSKY, Nicholas Stuart WILSON
-
Patent number: 11401335Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.Type: GrantFiled: January 15, 2020Date of Patent: August 2, 2022Assignees: AGENUS INC., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Ana M. Gonzalez, Nicholas S. Wilson, Dennis J. Underwood, Volker Seibert, Olivier Léger, Marc Van Dijk, Roberta Zappasodi, Taha Merghoub, Jedd David Wolchok, David Schaer, Gerd Ritter, Takemasa Tsuji
-
Patent number: 11359028Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and/or human GITR receptor (GITR), including multispecific antibodies that bind, e.g., to OX40 and GITR, and compositions comprising such antibodies. The antibodies disclosed herein modulate OX40 and/or GITR activity e.g., enhance, activate, induce, reduce, deactivate, or inhibit OX40 and/or GITR activity. The present disclosure also provides methods for treating disorders, such as cancer, autoimmune diseases or disorders, or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and/or human GITR and modulates OX40 and/or GITR activity.Type: GrantFiled: May 9, 2019Date of Patent: June 14, 2022Assignees: AGENUS INC., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Nicholas S. Wilson, Jeremy D. Waight, Dennis J. Underwood, Ekaterina V. Breous-Nystrom, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Marc Van Dijk
-
Patent number: 11345755Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: April 24, 2020Date of Patent: May 31, 2022Assignees: Agenus Inc., Ludwig Institute for Cancer Research Ltd., Memorial Sloan-Kettering Cancer CenterInventors: Marc Van Dijk, Cornelia Anne Mundt, Gerd Ritter, Jedd David Wolchok, Taha Merghoub, Roberta Zappasodi, Rikke Bæk Holmgaard, David Schaer, David Adam Savitsky, Nicholas Stuart Wilson
-
Patent number: 11332536Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.Type: GrantFiled: February 7, 2020Date of Patent: May 17, 2022Assignees: AGENUS INC., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Marc Van Dijk, Ekaterina V. Breous-Nystrom, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Hao Tang, David A. Savitsky, Nicholas S. Wilson
-
Publication number: 20220098316Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.Type: ApplicationFiled: September 1, 2021Publication date: March 31, 2022Inventors: Marc VAN DIJK, Ekaterina V. Breous-Nystrom, Volker Seibert, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Hao Tang, David A. Savitsky, Jeremy Waight, Nicholas S. Wilson
-
Patent number: 11267889Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: April 24, 2020Date of Patent: March 8, 2022Assignees: Agenus Inc., Ludwig Institute for Cancer Research Ltd., Memorial Sloan-Kettering Cancer CenterInventors: Marc Van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, David Adam Savitsky, Nicholas Stuart Wilson